SITE015-0322

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-03-18

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 10); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-10 (study day 39); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-22 (study day 509); relationship: not assessed

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-29 (study day 516); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-12-10 (study day 619); relationship: Y

Data queries

No data queries.